118 related articles for article (PubMed ID: 3988396)
1. Elimination kinetic of high polar metabolites pool of quinidine from human serum.
Camsonne R; Moulin MA; Charbonneau P; Bazin C
Int J Clin Pharmacol Ther Toxicol; 1985 Feb; 23(2):74-5. PubMed ID: 3988396
[TBL] [Abstract][Full Text] [Related]
2. Dose-dependent kinetics of quinidine in the perfused rat liver preparation. Kinetics of formation of active metabolites.
Yu VC; de Lamirande E; Horning MG; Pang KS
Drug Metab Dispos; 1982; 10(6):568-72. PubMed ID: 6130901
[TBL] [Abstract][Full Text] [Related]
3. [Elimination half-life of 3-hydroxyquinidine in man].
Camsonne R; Moulin MA; Bazin C; Charbonneau P; Drieu L; Pedailles S; Briand A
Therapie; 1983; 38(1):115-6. PubMed ID: 6867995
[No Abstract] [Full Text] [Related]
4. Specific determination of quinidine and (3S)-3-hydroxyquinidine in human serum by high-pressure liquid chromatography.
Drayer DE; Restivo K; Reidenberg MM
J Lab Clin Med; 1977 Nov; 90(5):816-22. PubMed ID: 908870
[TBL] [Abstract][Full Text] [Related]
5. Fetal supraventricular tachycardia treated with high-dose quinidine: toxicity associated with marked elevation of the metabolite, 3(S)-3-hydroxyquinidine.
Killeen AA; Bowers LD
Obstet Gynecol; 1987 Sep; 70(3 Pt 2):445-9. PubMed ID: 3627599
[TBL] [Abstract][Full Text] [Related]
6. Disposition kinetics of dihydroquinidine following quinidine administration.
Ueda CT; Williamson BJ; Dzindzio BS
Res Commun Chem Pathol Pharmacol; 1976 Jun; 14(2):215-25. PubMed ID: 940955
[TBL] [Abstract][Full Text] [Related]
7. Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects.
Vozeh S; Uematsu T; Guentert TW; Ha HR; Follath F
Clin Pharmacol Ther; 1985 May; 37(5):575-81. PubMed ID: 3987181
[TBL] [Abstract][Full Text] [Related]
8. Kinetics and dynamics of quinidine-N-oxide in healthy subjects.
Ha HR; Vozeh S; Uematsu T; Guentert TW; Follath F
Clin Pharmacol Ther; 1987 Sep; 42(3):341-5. PubMed ID: 3621790
[TBL] [Abstract][Full Text] [Related]
9. Total and unbound concentrations of quinidine and 3-hydroxyquinidine at steady state.
Wooding-Scott RA; Visco J; Slaughter RL
Am Heart J; 1987 Feb; 113(2 Pt 1):302-6. PubMed ID: 3812182
[TBL] [Abstract][Full Text] [Related]
10. Lack of effect of smoking on the metabolism and pharmacokinetics of quinidine in patients.
Edwards DJ; Axelson JE; Visco JP; vanEvery S; Slaughter RL; Lalka D
Br J Clin Pharmacol; 1987 Mar; 23(3):351-4. PubMed ID: 3567051
[TBL] [Abstract][Full Text] [Related]
11. Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered?
Rameis H
Int J Clin Pharmacol Ther Toxicol; 1985 Mar; 23(3):145-53. PubMed ID: 3997300
[TBL] [Abstract][Full Text] [Related]
12. [Relative bioavailability and influence of a quinidine retard-formulation on blood-pressure and ECG in healthy volunteers (author's transl)].
Knapp W; Lechleitner P
Arzneimittelforschung; 1981; 31(9):1482-6. PubMed ID: 7197960
[TBL] [Abstract][Full Text] [Related]
13. Greater quinidine-induced QTc interval prolongation in women.
Benton RE; Sale M; Flockhart DA; Woosley RL
Clin Pharmacol Ther; 2000 Apr; 67(4):413-8. PubMed ID: 10801251
[TBL] [Abstract][Full Text] [Related]
14. The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine.
Edwards DJ; Lavoie R; Beckman H; Blevins R; Rubenfire M
Clin Pharmacol Ther; 1987 Jan; 41(1):68-73. PubMed ID: 3802708
[TBL] [Abstract][Full Text] [Related]
15. The bioavailability and kinetics of dihydroquinidine in patients with heart disease.
Regazzi Bonora M; Salerno JA; Rondanelli R; Cristiani D; Chimienti M
Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):212-8. PubMed ID: 7095920
[TBL] [Abstract][Full Text] [Related]
16. Rapid elimination of quinidine in pediatric patients.
Szefler SJ; Pieroni DR; Gingell RL; Shen DD
Pediatrics; 1982 Sep; 70(3):370-5. PubMed ID: 7110810
[TBL] [Abstract][Full Text] [Related]
17. Assessment of quinidine gluconate for nonlinear kinetics following chronic dosing.
Russo J; Russo ME; Smith RA; Pershing LK
J Clin Pharmacol; 1982; 22(5-6):264-70. PubMed ID: 7107973
[TBL] [Abstract][Full Text] [Related]
18. Modulation of effect of dietary salt on prehepatic first-pass metabolism: effects of beta-blockade and intravenous salt loading.
Fromm MF; Darbar D; Dell'Orto S; Roden DM
J Pharmacol Exp Ther; 1999 Jul; 290(1):253-8. PubMed ID: 10381784
[TBL] [Abstract][Full Text] [Related]
19. Diurnal oscillations in the serum and salivary levels of quinidine.
Rao BR; Rambhau D
Arzneimittelforschung; 1995 Jun; 45(6):681-3. PubMed ID: 7646570
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of 3-hydroxyquinidine following chronic quinidine therapy.
Ackerman BH; Olsen KM; Pappas AA
DICP; 1991; 25(7-8):867-9. PubMed ID: 1949948
[No Abstract] [Full Text] [Related]
[Next] [New Search]
